Cancer patients get continued access to promising drug
NCT ID NCT02934568
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enrolled, and they must be getting clinical benefit as judged by their doctor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib (LEE011)
What this could lead to
If successful, this study allows patients with advanced cancers to keep receiving a treatment that is already working for them, potentially extending their benefit.
What could go wrong
This is a small rollover study (22 patients) with no control group, so results may not apply broadly. Side effects like liver issues or serious adverse events are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Broome Oncology
Johnson City, New York, 13790, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
St Jude Childrens Research Hospital
Memphis, Tennessee, 38105, United States
-
The Regents of the Uni of Michigan
Ann Arbor, Michigan, 48109-5930, United States
-
University Of Alabama At Birmingham
Birmingham, Alabama, 35294-3300, United States